vs
CareDx, Inc.（CDNA）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是CareDx, Inc.的1.3倍（$140.6M vs $108.4M）。VERACYTE, INC.净利率更高（29.3% vs -3.8%，领先33.0%）。CareDx, Inc.同比增速更快（25.2% vs 18.5%）。过去两年CareDx, Inc.的营收复合增速更高（22.7% vs 20.5%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CDNA vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.3倍
$108.4M
营收增速更快
CDNA
高出6.6%
18.5%
净利率更高
VCYT
高出33.0%
-3.8%
两年增速更快
CDNA
近两年复合增速
20.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $140.6M |
| 净利润 | $-4.1M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | -5.6% | 26.4% |
| 净利率 | -3.8% | 29.3% |
| 营收同比 | 25.2% | 18.5% |
| 净利润同比 | -104.7% | 704.8% |
| 每股收益（稀释后） | $-0.08 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAVCYT
| Q4 25 | $108.4M | $140.6M | ||
| Q3 25 | $100.1M | $131.9M | ||
| Q2 25 | $86.7M | $130.2M | ||
| Q1 25 | $84.7M | $114.5M | ||
| Q4 24 | $86.6M | $118.6M | ||
| Q3 24 | $82.9M | $115.9M | ||
| Q2 24 | $92.3M | $114.4M | ||
| Q1 24 | $72.0M | $96.8M |
净利润CDNAVCYT
| Q4 25 | $-4.1M | $41.1M | ||
| Q3 25 | $1.7M | $19.1M | ||
| Q2 25 | $-8.6M | $-980.0K | ||
| Q1 25 | $-10.4M | $7.0M | ||
| Q4 24 | $87.7M | $5.1M | ||
| Q3 24 | $-10.6M | $15.2M | ||
| Q2 24 | $-4.6M | $5.7M | ||
| Q1 24 | $-19.9M | $-1.9M |
毛利率CDNAVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率CDNAVCYT
| Q4 25 | -5.6% | 26.4% | ||
| Q3 25 | -0.2% | 17.4% | ||
| Q2 25 | -12.8% | -4.0% | ||
| Q1 25 | -15.8% | 2.5% | ||
| Q4 24 | 97.5% | 3.5% | ||
| Q3 24 | -16.6% | 10.4% | ||
| Q2 24 | -7.9% | 4.0% | ||
| Q1 24 | -31.3% | -4.8% |
净利率CDNAVCYT
| Q4 25 | -3.8% | 29.3% | ||
| Q3 25 | 1.7% | 14.5% | ||
| Q2 25 | -9.9% | -0.8% | ||
| Q1 25 | -12.2% | 6.2% | ||
| Q4 24 | 101.3% | 4.3% | ||
| Q3 24 | -12.8% | 13.1% | ||
| Q2 24 | -5.0% | 5.0% | ||
| Q1 24 | -27.6% | -1.9% |
每股收益（稀释后）CDNAVCYT
| Q4 25 | $-0.08 | $0.50 | ||
| Q3 25 | $0.03 | $0.24 | ||
| Q2 25 | $-0.16 | $-0.01 | ||
| Q1 25 | $-0.19 | $0.09 | ||
| Q4 24 | $1.60 | $0.07 | ||
| Q3 24 | $-0.20 | $0.19 | ||
| Q2 24 | $-0.09 | $0.07 | ||
| Q1 24 | $-0.38 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $303.1M | $1.3B |
| 总资产 | $413.2M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAVCYT
| Q4 25 | $177.2M | $362.6M | ||
| Q3 25 | $194.2M | $315.6M | ||
| Q2 25 | $186.3M | $219.5M | ||
| Q1 25 | $230.9M | $186.1M | ||
| Q4 24 | $260.7M | $239.1M | ||
| Q3 24 | $240.9M | $274.1M | ||
| Q2 24 | $228.9M | $235.9M | ||
| Q1 24 | $215.9M | $209.2M |
总债务CDNAVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益CDNAVCYT
| Q4 25 | $303.1M | $1.3B | ||
| Q3 25 | $311.1M | $1.3B | ||
| Q2 25 | $327.4M | $1.2B | ||
| Q1 25 | $379.3M | $1.2B | ||
| Q4 24 | $378.4M | $1.2B | ||
| Q3 24 | $273.2M | $1.2B | ||
| Q2 24 | $264.7M | $1.1B | ||
| Q1 24 | $256.2M | $1.1B |
总资产CDNAVCYT
| Q4 25 | $413.2M | $1.4B | ||
| Q3 25 | $432.3M | $1.4B | ||
| Q2 25 | $444.3M | $1.3B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.3B | ||
| Q3 24 | $477.0M | $1.3B | ||
| Q2 24 | $466.8M | $1.2B | ||
| Q1 24 | $452.4M | $1.2B |
负债/权益比CDNAVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $48.8M |
| 自由现金流率自由现金流/营收 | — | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流CDNAVCYT
| Q4 25 | $21.4M | $52.6M | ||
| Q3 25 | $37.4M | $44.8M | ||
| Q2 25 | $9.9M | $33.6M | ||
| Q1 25 | $-26.6M | $5.4M | ||
| Q4 24 | $21.9M | $24.5M | ||
| Q3 24 | $12.5M | $30.0M | ||
| Q2 24 | $18.9M | $29.6M | ||
| Q1 24 | $-15.3M | $-9.0M |
自由现金流CDNAVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率CDNAVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度CDNAVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率CDNAVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 22.30× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | 0.25× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
